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Purpose: This study tested the hypothesis that a subset of secondary infrainguinal arterial reconstructions show
prohibitive failure rates.
Methods: Records of 79 consecutive patients, 44 men and 35 women, with a mean age of 60 years, who underwent
secondary infrainguinal bypass from 1992 to 2000 at the University of Michigan Hospital, were reviewed. Data were
analyzed with life-table analysis, logistic regression, and descriptive statistics.
Results: Secondary infrainguinal reconstructions were performed in patients who had undergone earlier ipsilateral
bypasses once (n  35) or twice (n  44). Among the prior procedures, 68% (n  54) were done at an institution other
than the authors’. Comorbidities included coronary artery disease (72%), tobacco use (77%), and diabetes mellitus (34%),
but no patient had hemodialysis-dependent renal failure. Disabling claudication, with average ankle brachial index of
0.48, had been the indication for the primary operation in 77% of cases. Femoral-popliteal bypass was the primary
procedure in 67%, with a prosthetic graft used in 62%. The mean patency duration of these earlier bypasses was 25
months. The indication for the final bypass was rest pain or tissue loss in 51% of patients, with an average ankle brachial
index of 0.37. The most common procedure was a femoral-distal bypass with autologous vein (63%). Mean patency
duration of the secondary bypasses was 30 months. Graft failure within 30 days of operation occurred in 22 patients
(28%), and amputation was necessitated in 86% of these patients. The presence of rest pain or tissue loss, when
accompanied with a history of early prior graft thrombosis in female patients, correlated with worse mean patency rates,
recurrent graft failure (P< .05), and a 94% amputation rate. Men in a similar setting incurred a 57% amputation rate. No
association of final patency existed with regard to age, number of prior bypasses, conduit types, tobacco use, or diabetes.
Conclusion: Secondary infrainguinal bypasses are associated with an increased rate of graft failure and significant limb
loss, particularly in those with a history of rest pain or tissue loss, female gender, and early prior graft failure. More
appropriate initial operations in carefully selected patients and aggressive postoperative graft surveillance is speculated to
improve these outcomes. (J Vasc Surg 2002;35:902-9.)
More patients will have lower extremity peripheral vas-
cular arterial occlusive disease develop as the population
ages, and many will come to operative bypass. Most series
of primary autologous vein infrainguinal bypass reconstruc-
tion report overall 5-year patency and limb salvage rates
between 70% and 85%, regardless of whether the vein
bypass is reversed, in situ, or in a nonreversed translocated
configuration.1-4 Prosthetic bypasses have lower patency
and limb salvage rates compared with autologous vein but
are suitable for the above-knee femoral-popliteal artery
bypass.5
Secondary infrainguinal bypass patency rates are gener-
ally inferior compared with primary bypasses, attributed
most often to severity of arterial disease.6-11 This may be
the result of less available autologous conduit, reoperative
fields, and less optimal arterial targets. The goal of this
study was to review a consecutive group of patients who
underwent secondary and tertiary infrainguinal bypasses
and to identify those factors related to early and late graft
failure.
METHODS
A retrospective medical record review was performed of
330 consecutive patients who underwent an infrainguinal
bypass between 1992 and 2000 at the University of Mich-
igan Hospital. In this series, 79 patients had undergone
earlier primary or secondary procedures before a final by-
pass, which became the subject of this study. Patients were
excluded from analysis if they had undergone a thrombec-
tomy or a graft salvage operation, such as a vein patch
angioplasty, as an isolated procedure. The University of
Michigan Institutional Review Board approved this inves-
tigation (#2000-0712).
Patient indications for bypass were classified as rest
pain/tissue loss or lifestyle-limiting claudication. Patient
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follow-up study was documented with symptom-free lower
extremity ischemia, ankle brachial indices (ABIs), and limb
salvage. Bypass conduit types were categorized as autolo-
gous vein (single and spliced), prosthetic (Dacron and
expanded polytetrafluoroethylene [ePTFE]), and compos-
ite (prosthetic and vein). Infrainguinal bypass targets were
categorized as femoral-to-popliteal artery, femoral-to-dis-
tal (tibial-peroneal) arteries, and combined inflow (eg, aor-
tofemoral bypass) and outflow (eg, femoral-popliteal by-
pass) procedures. Arteriographic studies were obtained in
all patients before the final bypass and were available for
analysis. No formal intraoperative or postoperative duplex
scan graft surveillance program was rigidly followed during
the study interval. Intraoperative assessment of graft ade-
quacy was at the discretion of the surgeon but, at a mini-
mum, included hand-held Doppler scan examination and
usually intraoperative arteriography (28 of 62 patients). No
formal duplex scan surveillance program was in place dur-
ing this study period. The operating surgeon determined
postoperative anticoagulant therapy, which usually in-
volved antiplatelet therapy and occasionally early heparin
administration followed by long-term warfarin sodium anti-
coagulation.
Statistical analysis. Data were entered into an Access
97 database (Microsoft, Redmond, Wash) and analyzed
with SAS version 8.2 (SAS Institute, Cary, NC). Descrip-
tive statistics were generated with summary tables for con-
tinuous data and frequency tables for dichotomous out-
comes. Post hoc tests to evaluate for type II errors were
performed with nQuery Advisor, version 4.0 (Statistical
Solutions, Sangus, Mass). Because the major outcomes of
interest were best expressed as patency rates for patients
who underwent procedures at different points of time and
because the number of subjects was limited, the analysis was
prepared with Kaplan-Meier product-limit estimates from
the PROC LIFETEST routine of the SAS program (Alli-
son, PD, Survival Analysis Using the SAS System, 1995
SAS Institute Inc). The primary analysis determined the
mean duration of patency for the final graft. Univariate
analysis was performed to evaluate the importance of co-
variates, including concurrent medical conditions, the in-
dications for each procedure, the types of procedures, and
the graft materials used and secondary interventions, in-
cluding angioplasty and stents. Covariates that were signif-
icantly associated (P  .05) with the duration of patency
were entered into a SAS logistic regression model with
PROC LOGISTIC, and the covariates were assessed to
determine those which were independently associated with
the outcomes of interest. With PROC LIFETEST, we
reran the survival analysis after stratifying for each of these
variables. The curves were compared with the log-rank test
of significance.
RESULTS
Patient demographics did not reveal a group at inordi-
nately high risk for bypass graft failure (Table I). The mean
patient age was 60 years, with 56% of patients men. To-
bacco use and coronary artery disease were prevalent; dia-
betes and hypercholesterolemia were less so. No patient
had hemodialysis-dependent renal failure. A known hyper-
coagulable state was present in only two patients (hyperho-
mocystinemia and antiphospholipid antibody syndrome).
Antiplatelet or anticoagulant therapy had been in effect in
30 and 26 patients, respectively, before the final bypass.
Postoperative anticoagulation was aspirin in 37 patients
and warfarin sodium in 38.
Prior bypasses. Most of the primary bypasses were
performed at an institution other than the authors’ (n 54;
68%). As indicated in Table II, a femoral-to-popliteal artery
bypass was done most commonly (67%), and a femoral-to-
distal artery bypass was less common (30%). Claudication
was the indication for the primary procedure in 77% of the
patients, with an average ipsilateral ABI of 0.48. Rest pain
or tissue loss affected the remaining 23%. Prosthetic grafts
were used in 62% of these procedures, and autologous vein
bypasses were performed in 38%. The mean patency dura-
tion of these primary bypasses was 25 months.
Forty-four patients had more than one bypass before
the final procedure. The indications for these procedures
were claudication in 57% and rest pain or tissue loss in 43%,
the latter being more prevalent in those with only one prior
bypass. Femoral-to-popliteal artery bypasses were more
common than distal artery bypasses (54% versus 38%) in
this group. Prosthetic grafts were used in 56%, autologous
vein in 36%, and a composite bypass in 8%. Mean bypass
patency duration was 25 months in this group of secondary
bypasses.
Final bypass. All of the final bypasses were done at the
authors’ institution. The indication for these procedures
included rest pain or tissue loss in 51% and claudication in
49% (Table II). The average ipsilateral ABI was 0.37.
Evaluation of the preoperative angiograms revealed com-
mon and deep femoral artery disease in 14%, a stenotic or
occluded superficial femoral artery in 91%, popliteal artery
disease in 37%, and trifurcation or tibial artery disease in
41%. A femoral-to-distal artery bypass was performed in
Table I. Demographics of patients who underwent
secondary infrainguinal bypass
Characteristics
Age (y) 60
Male:female gender 44:35
Coronary artery disease 72%
Tobacco use 77%
Diabetes mellitus 34%
Prior aortic surgery 9%
Chronic renal failure 0%
Hypercoagulation 1%
Hyperhomocystinemia 1%
Hypercholesteremia 31%
Prior carotid surgery 13%
Contralateral bypass 40%
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56%, followed by a femoral-to-popliteal artery bypass in
41%. Combined inflow and outflow procedures were per-
formed in the remaining 3%. Autologous vein was used in
64%, prosthetic grafts in 25%, and composite grafts in 11%
of these procedures. The mean postoperative ABI was 0.73.
The perioperative mortality rate was 2.5%, and five patients
died during the mean follow-up period of 30 months.
Graft success. The overall cumulative 5-year graft pa-
tency rate was 48% (Fig 1; Appendix I, online only) as
estimated with Kaplan-Meier analysis. Secondary proce-
dures were performed in 31 patients (40%), of which 13
were endovascular (thrombolysis or angioplasty or both)
and 18 were open embolectomy or patch angioplasty or
both. The presence of rest pain/tissue loss and a history of
prior graft occlusion within 30 days were associated with
significantly worse cumulative patency rates by Kaplan-
Meier estimates (Figs 2 and 3; Appendixes II and III,
online only). Univariate analysis of factors that were signif-
icantly associated with final graft patency included female
gender, indication, and prior early graft failure (Table III).
No significant differences in patency duration were found
with Kaplan-Meier estimates when comparing autologous
with prosthetic or composite grafts, nor with comparing
spliced vein with whole vein grafts (16 months versus 24
months; P  .38).
Graft occlusion was documented in 42 patients, result-
ing in 30 amputations (38%). However, 12 of these patients
maintained limb salvage, with an average follow-up period
of 51 months. Among the 30 amputations, 18 patients had
an original indication for bypass of claudication (10 pa-
tients had a final indication of claudication), and 15 of these
18 patients had a prosthetic conduit used for their first
bypass.
The sequence of prior grafting was evaluated in regard
to mean patency rates (eg, autologous followed by pros-
thetic, prosthetic followed by prosthetic, prosthetic fol-
lowed by autologous, or prosthetic followed by composite
bypass). Although the numbers in each group were too
small to provide any statistically valid conclusions, a trend
favored longer mean patency rates with use of autologous
tissue bypasses: autologous 3 autologous (47 months),
autologous3 prosthetic (36 months), prosthetic3 pros-
thetic (21 months), and prosthetic 3 composite (18
months).
Fig 1. Kaplan-Meier plot of cumulative graft patency.
Table II. Patient bypass specifics
N Conduit Target Indications
Average
ABI
(Preop)
Mean
patency
(mo)
Primary 79 Prosthetic (62%) 
autologous (38%)
Fem-pop (67%) 
fem-distal (30%)
Claudication (61%)
 RP/TL (39%)
0.48 25
Secondary 44 Prosthetic (56%) 
autologous (36%)
 composite (8%)
Fem-pop (54%) 
fem-distal (38%)
Claudication (65%)
 RP/TL (35%)
0.42 25
Final 79 Autologous (64%) 
prosthetic (25%) 
composite (11%)
Fem-distal (56%) 
fem-pop (41%)
RP/TL (51%) 
claudication (49%)
0.37 30
Preop, Preoperative; RP/TL, rest pain or tissue loss or both; fem, femoral; pop, popliteal.
JOURNAL OF VASCULAR SURGERY
May 2002904 Henke et al
Early graft failure. Perioperative graft failure, less
than 30 days after surgery, affected 22 patients (27%).
Indications for bypass in the group included seven patients
with claudication and 15 with rest pain/tissue loss. Ampu-
tation was necessitated in 86% of these patients, and early
prior graft failure was clearly associated with limb loss (P
.0001), whereas late graft failure was not (P  .328). A
logistic regression model predicting early recurrent final
graft failure that incorporated gender, prior early failure,
and an initial indication of rest pain or tissue loss was highly
predictive (likelihood ratio, P  .016; Table IV). Both the
initial indication (P  .037) and prior early failure (P 
.0015) were independently associated with early final graft
failure. Although gender failed to reach statistical signifi-
cance, female patients failed procedures almost twice as
often as male patients (37% versus 20%) and had limb loss in
94% versus 57% in male patients.
DISCUSSION
Operative therapy for ischemic lower extremity vascular
disease is on the basis of three primary indications: rest pain,
tissue loss, or lifestyle-limiting claudication. The last cate-
gory is where indication limits are often modified to accom-
modate mild ischemic pain in patients not willing or unable
to maintain an exercise program. The current report sug-
gests that once one commits to operative therapy, the
stakes increase if the primary bypass fails. In patients who
come to further operation, the symptoms are usually worse
Fig 2. Kaplan-Meier plot of cumulative graft patency versus indication for bypass. Note that indication of claudication
(solid line) was associated with significantly better final patency rates as compared with rest pain/tissue loss (dashed line;
P  .02).
Fig 3. Kaplan-Meier plot of cumulative graft patency versus history of prior early graft thrombosis. Note that early
failure (dashed line) was associated with significantly worse final graft patency rate as compared with no prior early graft
failure (solid line; P .002). Immediate differing of patency curves suggests that recurrent early graft failure occurred.
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than the original indications for bypass, with most patients
in this series ultimately having rest pain or tissue loss
develop as the indication for a final bypass.
In this study, the final secondary infrainguinal bypasses
were associated with significantly lower patency rates and
limb salvage rates compared with primary bypass series.1-3
However, the reported patency and limb salvage rates in
our experience were generally comparable with other series
that have analyzed secondary and tertiary bypasses, where
final patency rates ranged from 38% to 76%.6-11 Although
claudication may appear to have been a common indication
for many of the secondary bypasses, most of these patients
were debilitated, as evidenced by an average ABI of 0.45.
Reasons that bypass procedures may fail are multiple
but include inadequate inflow and outflow, conduit qual-
ity, and undiagnosed hypercoagulable states. We and other
investigators were unable to document that progressive
inflow was a major cause for graft failure,8 nor could we
correlate graft failure to arterial outflow level. We found no
relation between ongoing tobacco use and graft failure, as
other investigators have reported,12 nor an increased failure
rate in patients with diabetes.13 In this series and in others,6
one of the most influential factors for graft failure, particu-
larly early graft failure, was an initial presentation of rest
pain or tissue loss. This failure is expected because these
patients usually have extensive and diffuse multilevel vascu-
lar disease. However, when distal bypasses are performed
primarily, patency and limb salvage rates are comparable
with more proximal bypasses,1,3,12 which suggests the ex-
tent of arteriographic disease is not always predictive of
outcomes.6,14 Thus, the constellation of rest pain or tissue
loss confers a worse outcome that is not always measurable
angiographically.
Patients with prior graft occlusions within 30 days of
operation were significantly more likely to have subsequent
secondary or tertiary graft failures and decreased final graft
patency and limb salvage rates. Robinson and colleagues15
documented poor graft patency rates after early primary
graft thrombosis, and their results suggested that graft
replacement is more efficacious than thrombectomy alone.
Early graft occlusions are usually considered the result of
technical errors. However, it seems unlikely that different
surgeons in our series, from two institutions in 68% of our
cases, would commit critical technical errors in the same
patient. The failure rate is possibly related to factors not
readily evident from this study, such as undiagnosed hyper-
coagulable states or inadequate intraoperative graft assess-
ment. Interestingly, no significant difference in final pa-
tency was found in comparing those patients with a
completion intraoperative arteriogram versus a handheld
Doppler examination.
Female gender in this series was associated with signif-
icant increases in early recurrent graft failure with logistic
regression modeling and was statistically significant with
univariate analysis. This finding is in contrast to other
authors who specifically evaluated gender influence on
patency and limb salvage rates in primary bypasses16 but did
not evaluate secondary bypasses.6-11 What biologic factor
may be most important in compromising bypass patency is
unclear, but a recent report suggests that women undergo-
ing hormone replacement had significantly worse primary
patency rates.17
Although it was not assayed for in this series, an intrigu-
ing possibility is the relation between increased incidence of
graft failure and the presence of elevated von Willebrand
levels and C-reactive protein levels.18,19 Existence of an
underlying hypercoagulable disorder was reflected in two
prospective studies, where 10% to 12% of patients were
found to harbor a hypercoagulable state, particularly
younger patients with advanced atherosclerosis.20,21 Un-
fortunately, hypercoagulable disorders were not routinely
screened in patients of this series.
Patients with recurrent bypass failures were more likely
to undergo an amputation, especially in those with an early
graft failure, where 86% had limb loss. Graft failure in
general is directly associated with subsequent limb loss13
and increased mortality.4,14 Important to note is that none
of the patients in this series had hemodialysis-dependent
renal failure. Given the bias of the authors’ practice, these
patients may have had earlier amputations and were never
considered for a reoperative bypass. Certainly, those pa-
tients with peripheral vascular occlusive disease and end-
stage renal failure have high mortality rates from their
underlying condition.14
In contrast to several other reports, no direct relation-
ship was found between conduit type and final graft paten-
cy.4,6,7 The subgroups in this series may have been too
small to reveal such relationships, and because of the vari-
Table III. Variables assessed for effect on final graft
patency with log-rank test
Test variable P value
Female gender .0399*
Presence of diabetes .7023
Presence of cardiac disease .8137
Tobacco use .7558
Disease extent: femoral versus popliteal versus
tibial with arteriography
.1908
Number of prior bypasses .900
Primary indication: claudication versus RP/TL .0031*
Primary bypass conduit: autologous versus
prosthetic versus composite
.0585
Primary procedure: femoral to popliteal versus
femoral to distal
.5619
Final indication: claudication versus RP/TL .0325*
Final bypass conduit: autologous versus
prosthetic versus composite
.7748
Final procedure: femoral to popliteal versus
femoral to distal
.9404
Postoperative anticoagulation: Coumadin versus
aspirin
.0636
Intraoperative assessment: Doppler versus
arteriogram
.140
Preoperative angioplasty .8033
Prior early bypass failure .0234*
*Factors assessed with Kaplan-Meier estimates for effect of final graft pa-
tency duration. RP/TL, Rest pain or tissue loss or both.
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ous combinations of conduits analyzed, a type II analytic
error exists. Autologous vein is reported to be the best
conduit if available, including upper extremity vein and
spliced vein.1-4,6 Most of the final bypasses in this series
were to the infrageniculate arteries where vein conduit is
clearly preferred. However, prosthetic grafts may be the
only option if no vein is available. Other investigators have
documented reasonable efficacy with ePTFE and adjuvant
anticoagulation.6,8 Similarly, the use of distal vein patches
with ePTFE conduits for infrageniculate bypasses com-
bined with oral anticoagulation has been reported in one
series with promising patency rates at 3 years of follow-up
study.22 However, the fact that prosthetic grafts cannot be
reliably followed with a surveillance duplex scan program to
detect prethrombotic graft failure is a distinct disadvan-
tage.23
The sequence of graft type placements revealed a trend
toward better final patency rates if the first bypass was
autologous vein. The worst outcomes occurred with com-
posite prosthetic vein bypasses. Other investigators also
have documented that composite bypasses have low 2-year
patency rates (12% to 37%).9,24 Jackson and colleagues25
recently reported that patients with a failed ePTFE bypass
were more likely to have limb-threatening ischemia develop
and come to an amputation when compared with those
with failed autologous vein grafts. Perhaps the failing pros-
thetic graft may be a nidus for continued distal vessel
embolization. Our findings support the tenet that one
should use restraint in considering use of prosthetic grafts
in treatment of claudication. Prosthetic graft reconstruc-
tions that were done as a primary treatment for claudication
accounted for 50% of the amputations in this series.
From this report, several empirical recommendations
can be made. First, primary therapy for most patients with
claudication should be risk factor modification, particularly
tobacco cessation, cholesterol reduction, and an exercise
program.26
Second, patients with early graft failure should undergo
a hypercoagulable work-up, and postoperative oral antico-
agulation should be considered if no technically obvious
cause for the initial graft failure is found.18,19,27 Indeed,
oral anticoagulation in a prospective study of high risk cases
has been shown to increase graft patency rates.28 Although
this study did not specifically address graft assessment pro-
tocols, intraoperative and postoperative duplex scan graft
surveillance should be performed routinely because it has
been well documented to ensure better graft patency and
limb salvage.23,29 Once a bypass thromboses, thrombolytic
therapy even with postlysis angioplasty or operative revision
rarely results in long-term patency.30
Third, consideration of primary amputation should be
entertained in female patients with a history of an early prior
bypass failure, rest pain/tissue loss, and a lack of autologous
vein for a subsequent bypass. This subgroup in this series
had a 100% secondary graft failure rate and a 94% amputa-
tion rate. Repeated surgery may be unwise in these patients,
particularly with the success of contemporary amputation
rehabilitation programs. This may be viewed as controver-
sial, given the report by Ouriel, Fiore, and Geary31 that
suggests all patients should be given the bypass option
rather than primary amputation. However, their study dis-
tinctly excluded secondary bypasses.
Although high graft failure rates have been docu-
mented in patients needing a secondary infrainguinal by-
pass, 62% of this series’ patients avoided amputation. Indi-
vidualizing patient therapy, with incorporation of the
previous recommendations, should improve the results of
secondary infrainguinal bypasses.
We thank S. Proctor for technical assistance.
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DISCUSSION
Dr Bruce Gewertz (Chicago, Ill). I take the privilege as a
senior member to ask some unfair questions. I was intrigued with
the title of your paper, which is “prohibitive failure,” and I assume
that would suggest that secondary bypasses should be “prohibit-
ed,” when in fact, an overall 67% limb salvage rate for patients who
come to you in despair with a failed bypass graft is actually a
reasonable therapy. I am a little concerned that that title gives a
spin to otherwise very clear and compelling data that would
suggest that although these bypasses are problematic that they do
in fact salvage nearly 70% of the limbs in these patients.
Further, I have no issues with your conclusions, but I wonder
if you could speculate on whether the unique status of a major
referral center maybe selects out bad actors, that is, whether
physicians in the community, who might otherwise handle their
own secondary revascularization, are apt to pick out the highest
risk, least attractive options to refer to Ann Arbor.
I very much enjoyed your paper.
Dr Peter Henke. Thank you very much, Dr Gewertz. You
are absolutely right about the title, and in fact, for the paper, I have
changed it really to focus on the group that we found to have
almost 100% limb loss, that is, women with tissue loss and a history
of early prior failed bypass.
In terms of our patient population, I think you are also right.
We do tend to get patients who have had more recurrent graft
failures, and the stimulus for this study was my experience as a
fellow where we did three or four recurrent redo bypasses and every
one of them failed. So, I think we do see patients who have been to
numerous general and then vascular surgeons who referred them
to us.
Dr John Blebea (Hershey, Pa). That was a very nice presen-
tation. I have two questions. It seems from your data that almost
half of the patients that underwent redo operations were claudi-
cants, and of those, I think 38% had a prosthetic graft placed. I am
surprised that if they had their graft thrombose and all they had for
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symptoms was claudication, and no vein was available, that you
would go ahead and use prosthetic. Is your actual practice now for
patients without vein and with thrombosed grafts with only clau-
dication to try a bypass with prosthetic?
The second question is, did you break down the results, not
necessarily just by conduit type at the final operation? But did the
patients who had an initial prosthetic and then a redo with vein do
better than those patients who initially had a vein, the graft
occluded, and a secondary operation with a prosthetic?
Dr Henke. Thank you. To answer your last question first, we
actually did in the paper analyze the sequence and did find that
those who had a prosthetic followed by a prosthetic composite had
a significantly lower mean patency rate. Unfortunately, the group
numbers were small, and it did not achieve statistical significance.
There was a recent paper presented by Dr Jackson from Southwest-
ern at the Southern Association for Vascular Surgery suggesting
that if someone has a failed prosthetic graft, they often present with
more critical ischemia if that graft goes down compared with those
vein grafts that may occlude on their own. I think we also have seen
that same phenomenon.
In terms of the claudicants who required recurrent bypass,
some of the patients honestly do have such severe claudication that
they are surgical candidates. In terms of true limb salvage indica-
tions, I think in patients who are willing to undergo the risk of a
below-knee prosthetic and a failure, it might not be the worst
option. I think also combining—if you have to use prosthetic
below the knee—a distal vein patch angioplasty with a prosthetic
and then anticoagulation is reasonable.
Dr Tina Desai (Chicago, Ill). I very much enjoyed your
presentation as well. I have a question regarding your 38% of
patients that required an amputation. Did you break down what
percentage of those patients were originally operated on for clau-
dication versus limb salvage? I think this would be useful informa-
tion to know.
Dr Henke. Thank you, Dr Desai. No, that is an excellent
suggestion. We did not do that.
Dr Mark Mattos (Springfield, Ill). Peter, nice talk. Three
questions. Did you look at functional outcomes in the redo oper-
ations, the cost of the operation and the length of stay, and
whether or not you looked in your multivariate analysis at the
anatomic criteria for the bypass, whether or not you had one-vessel
runoff, two-vessel runoff, peroneal open only, and continuous flow
to the foot? Because I think that may help you decide who should
get a primary amputation and who should not.
Dr Henke. Thank you, Dr Mattos. We did not look directly
at functional outcomes. We did try to assess this with late postop-
erative ABIs on patients who had failed and who had not received
an amputation, and we got kind of mixed results. It was a little bit
subjective but suggested that many of these patients after bypass
were still quite impaired and again may argue in certain cases that
a primary amputation with a good prosthesis is a better option.
We did not analyze any of the cost analysis of this, but I can tell
you anecdotally from the four patients that all failed that when I
was a fellow they had many complications and long lengths of stay.
The angiographic data were not looked at in terms of scoring
analysis but rather whether they had femoral, superficial femoral
artery, popliteal, or tibial disease, but yours is a good suggestion.
Thank you.
Dr William Turnipseed (Madison, Wis). I have been in-
trigued over the last several months with the concept of therapeutic
dissection using the subintimal angioplasty technique for treating
patients at high risk for technical failure. I have really been amazed
at early success and salvage options that this technique may pro-
vide. At present, I do not think it is widely employed or well
understood. Have you used subintimal angioplasty as an option for
a secondary or tertiary limb salvage at all?
Dr Henke. Thank you, Dr Turnipseed. We have really pretty
limited experience with that at our institution as the angiogra-
phers/interventionalists tend to do most of the angioplasty. There
has not been one physician who has been really interested in that
technique, but that may be another option for these patients after
failed bypass and before amputation for limb salvage.
Moderator. Peter, the only patient group where we at a
Mayo would not do a repeat procedure would be those with
end-stage renal disease, and I notice that you were extremely lucky
and did not have a single patient in your series. You also had very
few diabetics. I wonder if you could comment on that. And then I
just cannot help noticing that you had the same bad result with
saphenous vein as with prosthetic graft. How do you explain that?
Dr Henke. I think the fact that we had a low number of
diabetics and no patients with end-stage renal failure probably
suggests a practice bias; that is, it may be that many of my partners
tended to offer these people an amputation rather than aggressive
limb salvage in those patients with hemodialysis-dependent renal
failure. As for the diabetics, I am not sure how to explain the low
incidence.
In terms of again getting back to Dr Blebea’s question and
yours, the autologous bypasses trended toward a better long-term
patency, but it just did not reach statistical significance.
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